
RAW SEQUENCE LISTING
ERROR REPORT



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following CRF diskette:

Application Serial Number:

09/234, 208A

Art Unit / Team No.:

1642

Date Processed by STIC:

19211

THE ATTACHED PRINTOUT EXPLAINS THE ERRORS DETECTED.

PLEASE BE SURE TO FORWARD THIS INFORMATION TO THE APPLICANTS BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANTS ALONG WITH A NOTICE TO COMPLY or,
- 2) CALLING APPLICANTS AND FAXING THEM A COPY OF THE PRINTOUT WITH A NOTICE TO COMPLY

THIS WILL INSURE THAT THE NEXT SUBMISSION RECEIVED FROM THEM WILL BE ERROR FREE.

IF YOU HAVE ANY FURTHER QUESTIONS, PLEASE CALL:

**MARK SPENCER 703-308-4212** 

## Raw Sequence Listing Error Summary

	ERROR DETECT	ED SUGGESTED CORRECTION	SERIAL NUMBER:	<u>09/234,2</u> 08H
A1	TN: NEW RULES CASE:	S: PLEASE DISREGARD ENGLISH "ALPHA" H	TEADERS, WHICH WERE INSER	IFD BY PTO SOFTWARE
1	Wrapped Nucleics	The number/text at the end of each line 'wr.	apped" down to the next line	- LO DI LIO GOI IMARE
		This may occur if your file was retrieved in a	a word processor after creation it	
		Please adjust your right margin to .3, as thi	s will prevent "wrapping".	
	•			
2	Wrapped Aminos	The amino acid number/text at the end of ea		kt line.
		This may occur if your file was retrieved in a	a word processor after creating it.	
		Please adjust your right margin to .3, as this	s will prevent "wrapping".	
3	Incorrect Line Length	The adec service that a first a first		
٠	Incorrect Line Length	The rules require that a line not exceed 72 c	haracters in length. This includes:	spaces.
4 <u></u>	Misaligned Amino Aci	d The numbering under each 5th amino acid is	s misaligned. This may be caused i	ny tha was at tak-
	Numbering	between the numbering. It is recommended	to delete any take and use and in	by the use of tabs
	•	The state of the s	to delete any tabs and use spacing	between the numbers.
5	Non-ASCII	This file was not saved in ASCII (DOS) lext,	as required by the Sequence Rule:	s.
		Please ensure your subsequent submission	is saved in ASCII text so that it can	be processed.
c	Madakla ka a u			
°	Variable Length	Sequence(s) contain n's or Xaa's which	represented more than one residu	10.
		As per the rules, each n or Xaa can only repr		
		Please present the maximum number of each		đ .
		indicate in the (ix) feature section that some	may be missing.	
7	_ Patentin ver. 2.0 "bug"	A "bug" in Patentin version 2.0 has caused th	00 <220 × <222 * * * * * * * * * * * * * * * * *	
		•	ette would automatically a per missi	ing from amino acid
		sequence(s) Normally, Pater	itin would automatically generate t	his section from the
		previously coded nucleic acid sequence. Ple	ase manually copy the relevant <2	20>-<223> section
		to the subsequent amino acid sequence.	•	
8	_ Skipped Sequences	Sequence(s) missing. If intentional, plea	ise use the following format for each	h skinned seguence:
	(OLD RULES)	(2) INFORMATION FOR SEQ ID NO:X:	to the tree tree to the tree to the tree tree to the tree tree to the tree tree tree tree tree tree tree	ii skipped sequence.
		(I) SEQUENCE CHARACTERISTICS:(Do not	insert any headings under *SEOU	ENCE CHARACTERISTICS
		(xI) SEQUENCE DESCRIPTION:SEQ ID NO:	Y.	ENCE CHARACTERISTICS")
		This sequence is intentionally skipped	^	
		The sequence is intentionally skipped		
		Please also adjust the "(iii) NUMBER OF SEQ	UENCES: response to include the	skipped sequence(s).
•	Cliferatio	·	· ·	
9	Skipped Sequences	Sequence(s) missing. If intentional, pleas	se use the following format for each	skipped sequence.
	(NEW RULES)	<210> sequence ld number	•	
		<400> sequence id number		
		000	•	
10	Use of n's or Xaa's	Lien of ala and an Varia hand a second as the second as th		
	(NEW RULES)	Use of n's and/or Xaa's have been detected in		
	(NETT NOLES)	Use of <220> to <223> is MANDATORY if n's o	or Xaa's are present.	
		In <220> to <223> section, please explain loca	tion of n or Xaa, and which residue	e n or Xaa represents.
11	Use of <213>Organism	Sequence(s) are missing this mandate	one field or its response	
	(NEW RULES)	ord missing this mandate	Ay held of its response.	
40			•	
12	Use of <220>Feature	Sequence(s) are missing the <220>Feature	re and associated headings.	
	(NEW RULES)	Use of <220> to <223> is MANDATORY if <213	SORGANISM is "Artificial" or "Unk	nown"
		Please explain source of genetic material in	<220> to <223> section.	
		(See "Federal Register," 6/01/98, Vol.	63, No. 104, pp. 29631-32)	(Sec. 1.823 of new Rules)
13	Palantia a a			_
.,	Patentin ver. 2.0 "bug"	Please do not use "Copy to Disk" function of	Patentin version 2.0. This cause	s a corrupted
		file, resulting in missing mandatory numeric iden	tiliers and responses (as indicated	on raw sequence listing).
		Instead, please use "File Manager" or any other		
		AKS-Biotechnology Systems Bra	nch- 5/15/99	

PAGE: 1

## RAW SEQUENCE LISTING PATENT APPLICATION US/09/234,208A

DATE: 10/21/1999 TIME: 12:07:08

INPUT SET: S33723.raw

This Raw Listing contains the General Information Section and those Sequences containing ERRORS.

```
Does Not Comply
                                                              Corrected Diskette Needed
  1.
                                        SEQUENCE LISTING
  2
  3
     (1)
            General Information:
         (i) APPLICANT: Clinton, Gail and Doherty, Joni Kristin
  5
         (ii) TITLE OF INVENTION: HER-2 BINDING ANTAGONISTS
         (iii) NUMBER OF SEQUENCES: 9
10
         (iv) CORRESPONDENCE ADDRESS:
11
12
                (A) ADDRESSEE: DAVIS WRIGHT TREMAINE
13
                (B) STREET: 1501 Fourth Avenue, 2600 Century Square
14
                (C) CITY: Seattle
15
                (D) STATE: Washington
16
                (E) COUNTRY: U.S.A.
17
               (F) ZIP: 98101
          (v) COMPUTER READABLE FORM:
19
20
               (A) MEDIUM TYPE: Floppy disk
21
               (B) COMPUTER: PC compatible
22
               (C) OPERATING SYSTEM: Windows95
23
               (D) SOFTWARE: Word
24
25
         (vi) CURRENT APPLICATION DATA:
26
               (A) APPLICATION NUMBER: to be assigned
               (B) FILING DATE: 19 January 1999
28
               (C) CLASSIFICATION:
29
       (viii) ATTORNEY/AGENT INFORMATION:
30
31
               (A) NAME: Oster, Jeffrey B.
32
               (B) REGISTRATION NUMBER: 32,585
33
               (C) REFERENCE/DOCKET NUMBER: OHSU-1
34
         (ix) TELECOMMUNICATION INFORMATION:
35
36
               (A) TELEPHONE: 206 628 7711
37
               (B) TELEFAX: 206 628 7699
```

### **ERRORED SEQUENCES FOLLOW:**

60 (2) INFORMATION FOR SEQ ID NO:2:

PAGE: 2

#### RAW SEQUENCE LISTING PATENT APPLICATION US/09/234,208A

DATE: 10/21/1999 TIME: 12:07:08

INPUT SET: S33723.raw

```
61
             (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 419

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: polypeptide

(b) TOPOLOGY: polypeptide
   62
   63
   64
   65
   66
   67
            (ii) MOLECULE TYPE: polypeptide
   68
            (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
   69
        Met Glu Leu Ala Ala Leu Cys Arg Trp Gly Leu Leu Leu Ala Leu Leu
  70
  71
                                              .10
       Pro Pro Gly Ala Ala Ser Thr Gln Val Cys Thr Gly Thr Asp Cys Lys
  72
  73
                   20 <del>20</del>
                                         25 25
                                                              30 30 misel great
       Leu Arg Leu Pro Ala Ser Pro Glu Thr His Leu Asp Met Leu Arg His
  74
  75
                                         40
                                                              45
       Leu Tyr Gln Gly Cys Gln Val Val Gln Gly Asn Leu Glu Leu Thr Tyr
  76
                                                                               humber
  77
                                     55
                                                          60
       Leu Pro Thr Asn Ala Ser Leu Ser Phe Leu Gln Asp Ile Gln Glu Val (See Leu 4
  78
  79
                                70
                                                     75
       Gln Gly Tyr Val Leu Cys Ala His Asn Gln Val Arg Gln Val Pro Leu
  80
  81
                            85
                                                 90
       Gln Arg Leu Arg Ile Val Arg Gly Thr Gln Leu Phe Glu Asp Asn Tyr
  82
  83
                                             105
       Ala Leu Ala Val Leu Asp Asn Gly Asp Pro Leu Agn Agn Thr Thr Pro
  84
       115 , 120
  85
       Val Thr Gly Ala Ser Pro Gly Gly Leu Arg Glu Leu Gln Leu Arg Ser
  86
  87
                                    135
      Leu Thr Glu Cys Leu Lys Gly Gly Val Leu Ile Gln Arg Asn Pro Gln
  88
  89
                                150
                                                     155
      Leu Cys Tyr Gln Asp Thr Ile Leu Trp Lys Asp Ile Phe His Lys Asn
  90
  91
                           165
                                                 170
      Asn Gln Leu Ala Leu Thr Leu Ile Asp Thr Asn Arg Ser Arg Ala Cys
  92
 93
                       180
                                            185
      His Pro Cys Ser Pro Cys Cys Lys Gly Ser Arg Cys Trp Gly Glu Ser
 94
 95
                   195
                                        200
      Ser Glu Asp Cys Gln Ser Leu Thr Arg Thr Val Cys Ala Gly Gly Cys
 96
 97
                                    215
      Ala Arg Cys Lys Gly Pro Leu Pro Thr Asp Cys Cys His Glu Gln Cys
 98
 99
                               230
      Ala Ala Gly Cys Thr Gly Pro Lys His Ser Asp Cys Leu Ala Cys Leu
100
101
                                                250
      His Phe Asn His Ser Gly Ile Cys Glu Leu His Cys Pro Ala Leu Val
102
103
                       260
                                            265
      Thr Tyr Asn Thr Asp Thr Phe Glu Ser Cys Pro Asn Pro Glu Gly Arg
104
105
                  275
                                        280
      Tyr Thr Phe Gly Ala Ser Cys Val Thr Ala Cys Pro Tyr Asn Lys Leu
106
107
                                   295
      Ser Thr Asp Val Gly Ser Cys Thr Leu Val Cys Pro Leu His Asn Gln
108
109
                               310
     Glu Val Thr Ala Glu Asp Gly Thr Gln Arg Cys Glu Lys Cys Ser Lys
110
111
                          325
                                                330
     Pro Cys Ala Arg Val Gly Thr His Ser Leu Leu Pro Arg Pro Ala Ala
112
113
                                            345
                                                                 350
```

PAGE: 3

# RAW SEQUENCE LISTING PATENT APPLICATION US/09/234,208A

DATE: 10/21/1999 TIME: 12:07:08

IΝ	PUT	SET:	S33723.raw
0	Val	Leu	

		_												II	VPUI	SE1: 555/25.raw
114	Val	Pro	Val	Pro	Leu	Arg	Met	${\tt Gln}$	Pro	Gly	Pro	Ala	His	Pro	Val	Leu.
115				355					360					365		
116	Ser	Phe	Leu	Arg	Pro	Ser	Trp	Asp	Leu	Val	Ser	Ala	Phe	Tyr	Ser	T.011
117			370	_			_	375					380	- 7 -	DCI	шец
118	Pro	Leu	Ala	Pro	Leu	Asp	Pro	Thr	Ser	Va 1	Dro	тъ	500	D	**- 7	~
119		385				<u>F</u>	390		501	vai	FIO	395	ser	PLO	vai	ser
120	175 T	C1	7	<b>01</b>	<b>D</b>	_		_	_							
	Val	GIY	Arg	GIA	Pro	Asp	Pro	Asp	Ala	His	Val	Ala	Val	Asn	Leu	Ser
121	400					405					410					•
122	Arg	Tvr	Glu	Glv							410					415
123	•	4 -		1	•											